Mahamaya Lifesciences posts ₹16.72 cr profit in first annual report
The agrochemical firm grew annual revenue by 24.5% to ₹328.87 crore, while over half of its IPO proceeds remain parked in fixed deposits.
— 1 earlier story on Mahamaya Lifesciences Ltd. →What's new
- Annual revenue rose 24.5% to ₹328.87 crore on strong agrochemical sales.
- Net profit climbed 30.4% to ₹16.72 crore, with EPS at ₹8.43.
- ₹32.79 crore of the company's ₹61.96 crore IPO proceeds remains unutilised.
Why this matters
These are the first audited results for Mahamaya since its November 2025 listing. The company is showing early growth, but the fact that more than 50% of its IPO cash is still sitting in fixed deposits suggests a cautious approach to capital deployment.
What we're watching
- How the company plans to deploy the remaining ₹32.79 crore in IPO funds.
- Whether the 24.5% revenue growth rate sustains in the next two quarters.
- Any updates on new product launches in the agrochemical segment.
The full read
Mahamaya Lifesciences delivered its first annual report as a listed entity, showing a 24.5% jump in revenue to ₹328.87 crore. Net profit grew at a faster clip of 30.4% to reach ₹16.72 crore, yielding an EPS of ₹8.43. The agrochemical firm, which hit the BSE SME exchange in November 2025, maintains a clean bill of health with an unmodified audit opinion. Yet, the balance sheet reveals a conservative stance on expansion. Of the ₹61.96 crore raised in its IPO, ₹32.79 crore—or roughly 53%—remains unutilised and sits in fixed deposits. While the growth figures are positive, the company's next test is proving it can deploy that idle capital to maintain this momentum rather than letting it sit in the bank.
Questions answered
- What drove the company's revenue growth this year?
- The 24.5% increase in annual revenue to ₹328.87 crore was primarily driven by higher sales in the agrochemical segment.
- How much of the IPO money has been spent so far?
- Mahamaya raised ₹61.96 crore in its IPO. As of the end of March 2026, ₹32.79 crore remains unutilised and is currently held in fixed deposits.
- Did the auditor raise any concerns about these results?
- No. The auditor provided an unmodified opinion on the annual financial statements.
- What is the company's current earnings per share?
- The company reported an earnings per share of ₹8.43 for the financial year ended March 2026.
Story so far
All notes on MAHALIFE →- Today · 1:41 PM IST Mahamaya Lifesciences posts ₹16.72 cr profit in first annual report
- today Mahamaya Lifesciences confirms FY26 results with no surprises